Sierra Leone: WHO to Establish TB Vaccine Council
[Concord] Director General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus has announced plans to establish a new TB Vaccine Accelerator Council. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 20, 2023 Category: African Health Source Type: news

WHO announces plans to establish a TB Vaccine Accelerator council
The adverse impact of the COVID-19 pandemic on tuberculosis (TB) services has brought the urgency of vaccine development efforts into sharp focus. Speaking earlier today at a high-level panel on TB at the World Economic Forum, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced plans to establish a new TB Vaccine Accelerator Council. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 19, 2023 Category: Consumer Health News Source Type: news

Africa: WHO Announces Plans to Establish a TB Vaccine Accelerator Council
[WHO] The adverse impact of the COVID-19 pandemic on tuberculosis (TB) services has brought the urgency of vaccine development efforts into sharp focus. Speaking earlier today at a high-level panel on TB at the World Economic Forum, Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced plans to establish a new TB Vaccine Accelerator Council. (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - January 18, 2023 Category: Infectious Diseases Source Type: news

Africa: WHO Launches Council to Develop TB Vaccines
[UN News] The head of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, has unveiled plans to speed up the licensing and use of effective novel vaccines against tuberculosis (TB), the second leading infectious killer after COVID-19 and the 13th leading cause of death worldwide. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 18, 2023 Category: African Health Source Type: news

South Africa: South African Researchers Break New Ground in TB Vaccine Research - South African News Briefs - January 12, 2023
[allAfrica] Cape Town -- South African Researchers Bring Hope for Developing New TB Vaccines (Source: AllAfrica News: Tuberculosis)
Source: AllAfrica News: Tuberculosis - January 12, 2023 Category: Infectious Diseases Source Type: news

Clinical trials of new BCG vaccine for TB to start soon, says former CSIR chief
According to the India TB Report 2022, the number of 'incident TB patients' (new and relapse cases) notified during 2021 stood at 19.3 lakh. On the government's aim to make India TB-free by 2025, former director-general of the CSIR Dr Shekhar Mande said, "There is a very serious effort going across various agencies in the country. The department of health research, department of bio-technologies, CSIR, all of them are working towards TB-free 2025." (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 6, 2023 Category: Pharmaceuticals Source Type: news

Serum Institute seeks nod for adult TB vaccine
Once the drug controller approves the vaccine, the national technical advisory group on immunisation (NTAGI) will take a final call in its introduction in the immunisation programme. TUBERVAC-rBCG vaccine can be given to children, adolescents and adults. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2022 Category: Pharmaceuticals Source Type: news

Infant BCG Vaccine Protects Only Those Under Age 5 Years Infant BCG Vaccine Protects Only Those Under Age 5 Years
Although the BCG vaccine may keep severe forms of tuberculosis, meningitis, and miliary tuberculosis at bay, its efficacy and effectiveness against pulmonary tuberculosis are low.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 5, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news

Multidose BCG Protects Against COVID-19 in At-Risk Individuals
TUESDAY, Aug. 16, 2022 -- The multidose Bacillus Calmette-Guerin (BCG) vaccine offers protection against COVID-19 infection among COVID-19-unvaccinated individuals with type 1 diabetes, according to a study published online Aug. 15 in Cell Reports... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2022 Category: Pharmaceuticals Source Type: news

Why a Century-Old Vaccine Offers New Hope Against Pathogens
The B.C.G. tuberculosis vaccine may protect against Covid-19 and other infections by broadly bolstering the immune system. (Source: NYT Health)
Source: NYT Health - August 16, 2022 Category: Consumer Health News Authors: Roni Caryn Rabin Tags: your-feed-science Clinical Trials Diabetes Vaccination and Immunization Immune System Tuberculosis Coronavirus (2019-nCoV) Source Type: news

Nothing Lasts Forever, Including Infant BCG Vaccine Protection
(MedPage Today) -- Infants who received BCG [bacille Calmette-Guérin] vaccination at birth had protection against tuberculosis into early childhood, but that protection largely disappeared in only a few years, according to a meta-analysis... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 11, 2022 Category: American Health Source Type: news

STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

BCG Vaccine Benefit in Non –Muscle Invasive Bladder Cancer? BCG Vaccine Benefit in Non –Muscle Invasive Bladder Cancer?
Among patients with very high-risk but not high-risk disease, bacillus Calmette-Gu érin more effectively delayed time to progression compared with transurethral resection of the bladder.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 5, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

NIRT plans study on whether booster BCG can help prevent tuberculosis
The efficacy of BCG vaccination in newborns is well known and has a documented protective effect against meningitis and disseminated TB in children, Dr Padma Priyadarshini, Director, ICMR's National Institute for Research in Tuberculosis (NIRT) said. (Source: The Economic Times)
Source: The Economic Times - July 4, 2022 Category: Consumer Health News Source Type: news